Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 30;19(1):2169531. doi: 10.1080/21645515.2023.2169531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 9. — League chart of subgroup analysis. (a) Combined HR (95%CI) for PFS (upper triangle) and OS (lower triangle) of patients with PD-L1 1–49%; (b) Combined HR (95%CI) for PFS (upper triangle) and OS (lower triangle) of patients with PD-L1 ≥ 50%; the data in each cell is HR or OR (95% CI) comparing row definition processing and column definition processing. HR <1 and OR >1 indicate better results. Significant results are shown in bold. PFS: progression-free survival; OS: overall survival; HR: hazard ratio; OR: odds ratio; Atez: atezolizumab; Chem: chemotherapy; Nivo: nivolumab; Ipil: ipilimumab.